MBRX icon

Moleculin Biotech
MBRX

Overview Fund Activity

22 hedge funds and large institutions have $2.91M invested in Moleculin Biotech in 2023 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 3 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
22
Holders Change
-2
Holders Change %
-8.33%
% of All Funds
0.35%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
7
Reduced
3
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Squarepoint
1
Squarepoint
New York
$23K
2
HF
2
HRT Financial
New York
$15K
3
Citadel Advisors
3
Citadel Advisors
Florida
$30.6K
4
TSS
4
Two Sigma Securities
New York
$13K
5
Renaissance Technologies
5
Renaissance Technologies
New York
$91K

Top Sellers

1
Charles Schwab
1
Charles Schwab
California
$0
2
SCM
2
Sio Capital Management
New York
$971K
3
UBS Group
3
UBS Group
Switzerland
$0
4
Rockefeller Capital Management
4
Rockefeller Capital Management
New York
$0
5
CA
5
Clearstead Advisors
Ohio
$0
Name Holding Trade Value Shares
Change 		Shares
Change %
Rockefeller Capital Management
26
Rockefeller Capital Management
New York
– -$1K -119 Closed
CA
27
Clearstead Advisors
Ohio
– -$636 -40 Closed
GRP
28
Global Retirement Partners
California
– -$178 -11 Closed
1
2